Rare Neurological Disease Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Market is Segmented by Drug Type (Biologics and Small Molecules), Mode of Administration, and Geography.

Market Snapshot

Rare Neurological Disease Treatment Market 1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The rare neurological disease treatment market is expected to register a CAGR of 8.6% during the forecast period. A disease can be defined as rare if it has a prevalence of less than 5 per 10,000. Rare neurological disorders (RNDs) are vastly underdiagnosed, and effective treatment is often lacking. There are about 5000–8000 rare diseases, and about 5–8% of the European population is affected by a rare disease, many of which have neurological manifestations. Reflex Sympathetic Dystrophy Syndrome, Battaglia-Neri syndrome, Creutzfeldt Jakob Disease, Agnosia, Aicardi syndrome, Aicardi-Goutieres syndrome, are some of the neurological disorders. However, the diagnosis of rare neurological diseases involves several barricades, such as a lack of awareness about rare neurological diseases within the population. Rare diseases are creating huge healthcare and economic burden, worldwide.

According to the National Organization for Rare Disorders (NORD) Report, estimates around 7,000 known rare diseases lead to remarkable morbidity and mortality in 25 million Americans affected by them. In addition, about one-third of these are thought to include neurological components and symptoms. The increasing prevalence of rare neurological diseases and favorable government policies worldwide for speeding up development processes are the key driving factors in the limited neurological disease treatment market.

Scope of the Report

A disease can be defined as rare if it has a prevalence of less than 5 per 10,000. Rare neurological diseases (RNDs) are vastly underdiagnosed, and their effective treatment is often lacking. Rare neurological disease treatment market is segmented by drug type, mode of administration, and geography.

By Drug Type
Biologics
Small Molecules
By Mode of Administration
Injectables
Oral
Other Modes of Administration
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Biologics Segment is Expected to Hold a Major Market Share in the Rare Neurological Disease Treatment Market

  • The biologics segment holds a significant market share in the rare neurological disease treatment market. It is anticipated to show a similar trend over the forecast period due to the higher cost of biological drugs.
  • As per Australian Huntington's Disease Association, in Australia, over 1,800 people have Huntington's Disease, and approximately 9,000 individuals are at risk of developing the disease. Similarly, a very high concentration of Huntington's Disease has been found in Venezuela, where the prevalence of Huntington's Disease is about 700 per 100,000 population.
  • Increasing incidences of rare neurological diseases worldwide, increasing focus on fast-track approvals, technological advancements, and growing awareness regarding early diagnosis of rare neurological diseases are the key driving factors of the biologics segment.
Rare Neuro.png

North America is Expected to Hold a Significant Share in the Market in the Forecast Period

North America is expected to hold a major market share in the global rare neurological disease treatment market due to the availability of reimbursement, growing incidence of rare neurological diseases, and increasing research and development in this region. As per the Center for Rare Neurological Disease Research Report, the rare neurological diseases affect approximately 200,000 individuals in the United States. Furthermore, increasing healthcare spending and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Rare Neurological Disease Treatment Market 2

Competitive Landscape

The rare neurological disease treatment market is consolidated. The market consists of a few significant players who dominate the market. Some of the leading market players include CSL Ltd, Kedrion Biopharma Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Merz Pharma GmbH & Co. KGaA, Aquestive Therapeutics Inc., Bayer AG, Pfizer Inc., Novartis AG, Merck & Co. Inc. (EMD Serono Inc.), and Jazz Pharmaceuticals PLC.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Rare Neurological Diseases

      2. 4.2.2 Promising Pipeline Drugs for Treatment of Rare Neurological Diseases

      3. 4.2.3 Favorable Government Policies Worldwide for Speeding up Diagnostic Processes

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Type

      1. 5.1.1 Biologics

      2. 5.1.2 Small Molecules

    2. 5.2 By Mode of Administration

      1. 5.2.1 Injectables

      2. 5.2.2 Oral

      3. 5.2.3 Other Modes of Administration

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 US WorldMeds LLC (Solstice Neurosciences LLC)

      2. 6.1.2 CSL Ltd

      3. 6.1.3 Merz Pharma GmbH & Co. KGaA

      4. 6.1.4 Aquestive Therapeutics Inc.

      5. 6.1.5 Kedrion Biopharma Inc.

      6. 6.1.6 Bayer AG

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Novartis AG

      9. 6.1.9 Merck & Co. Inc. (EMD Serono Inc.)

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Rare Neurological Disease Treatment Market market is studied from 2018 - 2026.

The Rare Neurological Disease Treatment Market is growing at a CAGR of 8.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

CSL Ltd, Kedrion Biopharma Inc, US WorldMeds LLC (Solstice Neurosciences, LLC), Merz Pharma GmbH & Co. KGaA, Aquestive Therapeutics, Inc are the major companies operating in Rare Neurological Disease Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!